---
title: "SMO Clinplus Co., Ltd. (301257.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301257.SZ.md"
symbol: "301257.SZ"
name: "SMO Clinplus Co., Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T05:31:37.501Z"
locales:
  - [en](https://longbridge.com/en/quote/301257.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301257.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301257.SZ.md)
---

# SMO Clinplus Co., Ltd. (301257.SZ)

## Company Overview

SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company offers early modeling, preliminary preparation plan trial site initiation, on-site execution, and project management services. SMO ClinPlus CO.,LTD.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.smo-clinplus.com](https://www.smo-clinplus.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.36)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 25 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.09% |  |
| Net Profit YoY | 25.36% |  |
| P/B Ratio | 2.95 |  |
| Dividend Ratio | 0.35% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3782392808.68 |  |
| Revenue | 861065320.78 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.28% | B |
| Profit Margin | 13.28% | B |
| Gross Margin | 16.35% | D |
| Revenue YoY | 8.09% | C |
| Net Profit YoY | 25.36% | B |
| Total Assets YoY | 7.64% | B |
| Net Assets YoY | 8.55% | B |
| Cash Flow Margin | 35.16% | D |
| OCF YoY | 8.09% | C |
| Turnover | 0.58 | B |
| Gearing Ratio | 15.96% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - SMO Clinplus Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.09%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "25.36%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.95",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.35%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3782392808.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "861065320.78",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.28%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "13.28%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "16.35%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "8.09%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "25.36%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.64%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "8.55%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "35.16%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "8.09%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.58",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.96%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 33.61 | 4/25 | 38.91 | 34.30 | 29.57 |
| PB | 3.00 | 11/25 | 3.73 | 3.08 | 2.63 |
| PS (TTM) | 4.46 | 6/25 | 5.70 | 4.68 | 3.87 |
| Dividend Yield | 0.35% | 9/25 | 0.63% | 0.33% | 0.25% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | B | B | B |
| 03 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 04 | HitGen (688222.SH) | B | A | D | B | C | B |
| 05 | GEMPHARMATECH (688046.SH) | B | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-05-05T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 47.91 |
| Highest Target | 27.51 |
| Lowest Target | 27.51 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301257.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301257.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301257.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301257.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**